Epstein-barr virus latent membrane protein-1 oncogene deletion in post- transplantation lymphoproliferative disorders

American Journal of Pathology

Volumn 151, Issue 3, 1997, Pages 805-812

  Scheinfeld, Anke G ^a   Nador, Roland G ^a   Cesarman, Ethel ^a   Chadburn, Amy ^a   Knowles, Daniel M ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; ONCOPROTEIN;

ARTICLE; B CELL LYMPHOMA; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; DISEASE COURSE; EPSTEIN BARR VIRUS; GENE DELETION; GENE REARRANGEMENT; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT TRANSFORMATION; MULTIPLE MYELOMA; ONCOGENE; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; BLOTTING, SOUTHERN; CHILD; CHILD, PRESCHOOL; FEMALE; GENE DELETION; GENE REARRANGEMENT; HEART TRANSPLANTATION; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; TUMOR VIRUS INFECTIONS; VIRAL MATRIX PROTEINS;

EID: 0030964489     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Hanto DW, Sakamoto K, Purtilo DT, Simmons RI, Najarian JS: The Epstein-Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Surgery 1981, 90:204-213
2. Hanto DW, Frizzera G, Purtilo DT, Sakamoto K, Sullivan JL, Saemundsen AK, Klein G, Simmons RI, Narjarian JS: Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981, 41:4253-4261
3. Penn I: Malignant lymphomas in organ transplant recipients. Transplant Proc 1981, 13:736-738
4. Frizzera G: Atypical lymphoproliferative disorders. Neoplastic Hematopathology. Edited by DM Knowles. Baltimore, Williams and Wilkins, 1992, pp 459-495
5. Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA, Makowka L, Ho M, Locker J: The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporin A-prednisone immunosuppression. Am J Pathol 1988, 133:173-192
6. Ferry JA, Jacobson JO, Conti D, Delmoninco F, Harris NL: Lymphoproliferative disorders and hematologic malignancies following organ transplantation. Mod Pathol 1989, 2:583-592
7. Randhawa PS, Yousem SA, Paradis IL, Daube JA, Griffith BP, Locker J: The clinical spectrum, pathology and clonal analysis of Epstein-Barr virus-associated lymphoproliferative disorder in heart-lung transplant recipients. Am J Clin Pathol 1989, 92:177-185
8. Wilkinson AH, Smith JL, Hunsicker LG, Tobacman J, Kapelanski DP, Johnson M, Wright FH, Behrendt DM, Corry RJ: Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989, 47:293-296
9. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI: Increased incidence of lymphoproliferative disorders after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990, 323:1723-1728
10. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW, Hardesty RL, Atchison RW, Jaffe R, Bahnson HT: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984, 1:583-587
11. Knowles DM, Cesarman EC, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE: Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995, 85:552-565
12. Delecluse HJ, Kremmer E, Rouault JP, Cour C, Bornkamm G, Berger F: The expression of Epstein-Barr virus latent proteins is related to the pathologic features of post-transplant lymphoproliferative disorders. Am J Pathol 1995, 5:1113-1120
13. Dhir RK, Nalesnik MA, Demetris AJ, Randhawa PS: Latent membrane protein expression in posttransplant lymphoproliferative disease. Appl Immunohistochem 1995, 3:123-126
14. Purtilo DT, Strobach RS, Okano M, Davis JR: Biology of disease: Epstein-Barr virus-associated lymphoproliferative disorders. Lab Invest 1992, 67:5-23
15. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson K, Ritz J, Shapiro R, Rickinson A, Kieff E, Cohen J: Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989, 321:1080-1085
16. Fennewald S, van Santen V, Kieff E: Nucleotide sequence of a mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol 1984, 51:411-419
17. Hudson GS, Farrell PJ, Barrell BG: Two related but differentially expressed potential membrane proteins encoded by the EcoRI Dhet region of Epstein-Barr virus B95-9. J Virol 1985, 53:528-535
18. Wang D, Liebowitz D, Kieff E: An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1995, 43:831-840
19. Hu L, Chen F, Zheng F, Ernberg I, Cao S, Christensson B, Klein G, Winberg G: Clonability and tumorigenicity of human epithelial cells expressing the EBV-encoded membrane protein LMP1. Oncogene 1993, 8:1575-1583
20. Rickinson AB, Kieff E: Epstein-Barr virus. Virology. Edited by BN Fields. Philadelphia, Lippincott-Raven, 1996, pp 2397-2446
21. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker F, Kieff E, Rickinson A: Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991, 65:1107-1115
22. Peng M, Lundgren E: Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 1992, 7:1775-1782
23. Izumi K, Kaye K, Kieff E: Epstein-Barr virus recombinant molecular genetic analysis of the LMP1 amino-terminal cytoplasmic domain reveals a probable structural role, with no component essential for primary B-lymphocytes growth transformation. J Virol 1994, 68:4369-4376
24. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, Bachmann F, Odermatt B, Delsol G, Pallesen G: Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 1993, 82:2937-2942
25. Sandvej K, Peh S, Andresen B, Pallesen G: Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: high frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas. Blood 1994, 84:4053-4060
26. Hu LF, Zabarovsky ER, Chen F, Cao SL, Ernberg I, Klein G, Winberg G: Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from Chinese nasopharyngeal carcinoma. J Gen Virol 1991, 72:2399-2409
27. Chen M, Tsai C, Liang C, Shu C, Hang C, Sultzeanu D, Liu S, Chang Y: Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 1992, 7:2131-2140
28. Knecht H, Bachmann E, Joske DJL, Sahli R, Emery-Goodman A, Casanova J-L, Ziliac M, Bachmann F, Odermatt BF: Molecular analysis of the LMP (latent membrane protein) oncogene in Hodgkin's disease. Leukemia 1993, 7:580-585
29. Knecht H, Bachmann E, Brousset P, Rothenberger S, Einsele H, Lestou VS, Delsol G, Bachmann F, Ambras PF, Odermatt BF: Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorder. Oncogene 1995, 10:523-528
30. Chen WG, Chen YY, Bacchi CE, Alvarenga, Weiss LM: Genotyping of Epstein-Barr virus in Brazilian Burkitt's lymphoma and reactive lymphoid tissue: type A with a high prevalence of deletions within the latent membrane protein gene. Am J Pathol 1996, 148:17-23
31. Santon E, Manzanal AI, Campo E, Bellas C: Deletions in the Epstein-Barr virus latent membrane protein-1 oncogene in Hodgkin's disease. J Clin Pathol Mol Pathol 1995, 48:M184-M187
32. Martin J, Sugden B: Transformation by the oncogenic latent membrane protein correlates with its rapid turnover, membrane localization, and cytoskeletal association. J Virol 1991, 65:3246-3258
33. Moorthy R, Thorley-Lawson D: All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP1 are required for transformation of Rat-1 fibroblasts. J Virol 1993, 67:1638-1646
34. Greiner TC, Tierens A, Lytle DM, Gross T: Latent membrane protein-1 deletions are present in posttransplant lymphoproliferative disorders. Lab Invest 1995, 72:111A
35. Kingma DW, Weiss WB, Jaffe ES, Kumar S, Frekko K, Raffeld M: Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas. Blood 1996, 88:242-251
36. Smir BN, Hauke RJ, Bierman PJ, Gross TG, d'Amore F, Anderson JR, Greiner TC: Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttransplant lymphoproliferative disorders. Lab Invest 1996, 75: 575-588
37. Frank D, Cesarman EC, Liu YF, Michler RE, Knowles DM: Posttransplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus. Blood 1995, 85:1396-1403
38. Chadburn A, Cesarman E, Liu YF, Addonizio L, Hsu D, Michler RE, Knowles DM: Molecular genetic analysis demonstrates that multiple posttransplantation lymphoproliferative disorders occurring in one anatomic site in a single patient represent distinct primary lymphoid neoplasms. Cancer 1995, 75:2747-2756
39. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215
40. Southern EM: Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975, 98:503-517
41. Pelicci PG, Knowles DM, Dalla-Favera R: Lymphoid tumors displaying rearrangements of both immunoglobulin and T cell receptor genes. J Exp Med 1985, 162:1015-1024
42. Feinberg AP, Vogelstein B: A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983, 132:6-13
43. Raab-Traub N, Flynn K: The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986, 47:883-889
44. Korsmeyer SJ, Hieter PA, Ravetch JV, Polack DG, Waldmann TA, Leder P: Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells. Proc Natl Acad Sci USA 1981, 78:7096-7100
45. Lin JC, De BkK, Lin SH: Rapid and sensitive genotyping of Epstein-Barr virus using single-strand conformation polymorphism analysis of polymerase chain reaction products. J Virol Methods 1993, 43:233-246
46. Lin JC, Lin SC, De BK, Chan WP, Evatt BL: Precision of genotyping of Epstein-Barr virus by polymerase chain reaction using three gene loci (EBNA-2, EBNA-3c, and EBER): predominance of type A virus associated with Hodgkin's disease. Blood 1993, 81:3372-3381
47. Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A, Kieff E: Epstein-Barr virus types 1 and 2 differ in their EBNA-3a, EBNAS-b, and EBNA-3c genes. J Virol 1990, 64:4084-4092
48. Kyaw MT, Hurren L, Evans L, Moss DJ, Cooper DA, Benson E, Esmore D, Sculley TB: Expression of B-type Epstein-Barr virus in HIV-infected patients and cardiac transplant recipients. AIDS Res 1992, 8:1869-1874
49. Khanim F, Yao QY, Niedobitek G, Sihota S, Rickinson AB, Young LS: Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood 1996, 88:3491-3501